ASH: New Myeloma Regimens, AL Amyloidosis (CME/CE)
(MedPage Today) -- Add-on therapy with HDAC inhibitor improved outcomes in myeloma. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - December 15, 2014 Category: Consumer Health News Source Type: news
Prothena targets rare protein-misfolding disease in late-stage study
Elan Corp. spinout Prothena Corp. will take an experimental drug aimed at a rare protein-misfolding disease into a late-stage clinical trial, the company said Tuesday.
Prothena (NASDAQ: PRTA), whose operations are largely based in South San Francisco, said it will focus its drug on amyloid light-chain amyloidosis, or AL amyloidosis, in what's expected to be a 230-patient, Phase III study.
In the disease, misfolded amyloid proteins are deposited in tissue, causing progressive organ damage, including… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - December 2, 2014 Category: Hospital Management Authors: Ron Leuty Source Type: news
MRI and LV Remodelling in Cardiac AmyloidosisMRI and LV Remodelling in Cardiac Amyloidosis
Learn more about the morphological features and remodelling patterns of cardiac amyloidosis as seen with cardiac magnetic resonance imaging. Heart (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Alnylam begins DISCOVERY trial to track TTR mutation prevalence
Alnylam Pharmaceuticals has started the DISCOVERY trial of its investigational candidate ALN-TTRsc, to evaluate the prevalence of transthyretin (TTR) mutations in patients suspected of cardiac amyloidosis. (Source: Drug Development Technology)
Source: Drug Development Technology - September 24, 2014 Category: Pharmaceuticals Source Type: news
Hysterectomy Association Newsletter September 2014
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women.
Welcome to the September newsletter. Well, my dire predictions of the summer ending thankfully didn’t come to anything and we seem to be enjoying a late summer bonus here in the UK. Hopefully that’s the case elsewhere in the world too.
The Hysteria Writing Competition has finally closed to entries for this year and our judges are busy finishing off reading all the entries that arrived in the last week of August. When our...
Source: The Hysterectomy Association - September 11, 2014 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Newsletters Amyloidosis sleeping Source Type: news
Cardiac Amyloidosis: The Great ImitatorCardiac Amyloidosis: The Great Imitator
Three Mayo experts explain the three main types of cardiac amyloidosis and dispel some myths about the diagnosis and treatment of this rare condition. Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 8, 2014 Category: Cardiology Tags: Cardiology Roundtable Source Type: news
Amyloidosis – Can you help relieve the pressure?
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women.
Have you ever heard of amyloidosis? Don’t worry, I hadn’t either! The good news is you don’t have to be an expert on this rare and dangerous disease to help lighten the load of its victims.
Amyloidosis is a condition which causes an excessive build-up of proteins in the blood. These proteins form clusters called ‘amyloids’, which are deposited around the sufferer’s body, putting undue pressure on the system where they la...
Source: The Hysterectomy Association - September 2, 2014 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health Conditions Amyloidosis invisible illness Source Type: news
Cajal-Retzius cell loss and amyloidosis in Alzheimer's disease
(Neural Regeneration Research) Cajal-Retzius cells are reelin-secreting neurons in the marginal zone of the neocortex and hippocampus. However, the relationship between Cajal-Retzius cells and Alzheimer's disease is unknown. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 5, 2014 Category: Biology Source Type: news
Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
This study, published in the Dec. 25 issue of JAMA, is one of the first examples of successful repurposing of a generic drug to treat a rare disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 30, 2013 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news
Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
(Boston University Medical Center) A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine and Boston Medical Center demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced neurological decline and preserved the quality of life in patients with familial transthyretin amyloidosis. Diflunisal is an inexpensive and safe medication marketed over the past 40 years for arthritis and pain. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 24, 2013 Category: Global & Universal Source Type: news
Alnylam starts Phase II study of ALN-TTRsc for treatment of TTR-mediated amyloidosis
US-based Alnylam Pharmaceuticals has started a pilot Phase II trial with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin (TTR) gene in development for the treatment of TTR-mediated amyloidosis (ATTR). (Source: Drug Development Technology)
Source: Drug Development Technology - December 18, 2013 Category: Pharmaceuticals Source Type: news
Familial amyloidosis modeled in vitro using iPSC technology
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have generated the first known disease-specific induced pluripotent stem cell (iPSC) lines from a patient with familial transthyretin amyloidosis (ATTR). The findings, which are reported in Stem Cell Reports, may lead to new treatments for genetic diseases such as familial amyloidosis. iPSCs are a form of stem cells that come from skin or blood cells reprogrammed into cells that have the ability to become any type of tissue in the body... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 5, 2013 Category: Consumer Health News Tags: Stem Cell Research Source Type: news
Diagnosis: The Tell-Tale Green Heart
A very odd finding during routine surgery helps explain everything. (Source: NYT Health)
Source: NYT Health - November 1, 2013 Category: Consumer Health News Authors: By LISA SANDERS, M.D. Tags: Heart Amyloidosis Surgery and Surgeons Source Type: news
Alnylam completes enrolment in Phase II Transthyretin-Mediated Amyloidosis clinical trial
Alnylam Pharmaceuticals has completed enrolment in its Phase II trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). (Source: Drug Development Technology)
Source: Drug Development Technology - October 1, 2013 Category: Pharmaceuticals Source Type: news
Biomarker IDs Fibrotic Heart Failure (CME/CE)
ORLANDO (MedPage Today) -- Galectin-3 (Gal-3), a biomarker for fibrosis, may have a role in identifying heart failure caused by cardiac amyloidosis, researchers suggested. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 24, 2013 Category: Cardiology Source Type: news
